Inverted HS early entryApparently the support is holding. I think is going to test the 12 level resistance and it might break it out. But for now 12 is my target. Look how tight is my SL, it triggers only if a daily candle break down the trendline.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.79 USD
−262.14 M USD
59.61 M USD
101.75 M
About Arcutis Biotherapeutics, Inc.
Sector
CEO
Todd Franklin Watanabe
Headquarters
Westlake Village
Website
Founded
2016
FIGI
BBG00QN8K4M4
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
ARQT - long - momentum and catalyst playArcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targe
An upward trend of ARQT Target $8-10 Or $12Strong Trend Biotech treating skin problem!
large volume with good interest.
Hopefully it will go up more.
ARQT, Arcutis BiotherapeuticsTargets are in yellow/orange.
Should see a retracement to support below.
:)
January Gainers (ARQT, account up 1%)3rd gainer in January is ARQT . Holding period is 15 days (12/20/22-1/4/23). Account up 1%.
This month till today, my account is up 2.5%, average holding period is 12 days.
My trading method is mostly short term and is independent of market swings.
Will keep updating on my trades.
3-month trending patternIt starts to spike around the middle of each month, and peaks a little higher each time. Look at the price movement, the volume , and MACD indicator. If the price goes near 40, that's +35-38%, with relatively low risk.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ARQT is 10.82 USD — it has increased by 7.66% in the past 24 hours. Watch Arcutis Biotherapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arcutis Biotherapeutics, Inc. stocks are traded under the ticker ARQT.
ARQT stock has risen by 22.93% compared to the previous week, the month change is a 6.12% rise, over the last year Arcutis Biotherapeutics, Inc. has showed a 376.65% increase.
We've gathered analysts' opinions on Arcutis Biotherapeutics, Inc. future price: according to them, ARQT price has a max estimate of 29.00 USD and a min estimate of 12.00 USD. Watch ARQT chart and read a more detailed Arcutis Biotherapeutics, Inc. stock forecast: see what analysts think of Arcutis Biotherapeutics, Inc. and suggest that you do with its stocks.
ARQT reached its all-time high on Mar 20, 2020 with the price of 40.88 USD, and its all-time low was 1.76 USD and was reached on Dec 1, 2023. View more price dynamics on ARQT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ARQT stock is 10.53% volatile and has beta coefficient of 0.72. Track Arcutis Biotherapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Arcutis Biotherapeutics, Inc. there?
Today Arcutis Biotherapeutics, Inc. has the market capitalization of 1.22 B, it has increased by 1.31% over the last week.
Yes, you can track Arcutis Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Arcutis Biotherapeutics, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
ARQT earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.42 USD resulting in a 20.89% surprise. The estimated earnings for the next quarter are −0.28 USD per share. See more details about Arcutis Biotherapeutics, Inc. earnings.
Arcutis Biotherapeutics, Inc. revenue for the last quarter amounts to 44.76 M USD, despite the estimated figure of 37.62 M USD. In the next quarter, revenue is expected to reach 54.87 M USD.
ARQT net income for the last quarter is −41.54 M USD, while the quarter before that showed −52.33 M USD of net income which accounts for 20.63% change. Track more Arcutis Biotherapeutics, Inc. financial stats to get the full picture.
No, ARQT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 296.00 employees. See our rating of the largest employees — is Arcutis Biotherapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arcutis Biotherapeutics, Inc. EBITDA is −179.41 M USD, and current EBITDA margin is −401.34%. See more stats in Arcutis Biotherapeutics, Inc. financial statements.
Like other stocks, ARQT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arcutis Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arcutis Biotherapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arcutis Biotherapeutics, Inc. stock shows the neutral signal. See more of Arcutis Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.